US4584320A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
Assignee: Individual
•
Filing: 1985-01-03
•
Granted: 1986-04-22
•
Expires: 2005-01-03
Abstract
Abstract A method for the treatment of asthma, nasal congestion and anaphylactic shock involves nasal or oral administration of 8,11,14,17-eicosatetraenoic acid. Pharmaceutical compositions for this purpose are prepared containing 8,11,14,17-eicosatetraenoic acid and pharmaceutically acceptable vehicles, as well as, preferably, a suitable anti-oxidant.
Inventors
- 👤 David Rubin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 22:49
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
40 words
A composition for the treatment of conditions caused by excessive release of SRS-A, consisting essentially of an amount effective to inhibit relase of SRS-A of 8,11,14,17-eicosatetraenoic acid or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable vehicle.
Claim 2
Dependent Claim
40 words
A composition for the treatment of conditions caused by excessive release of SRS-A, consisting essentially of an amount effective to inhibit relase of SRS-A of 8,11,14,17-eicosatetraenoic acid or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable vehicle.
Claim 3
Dependent Claim
25 words
A composition in accordance with claim 1, wherein said pharmaceutically acceptable vehicle is chosen such as to permit administration of the composition as an inhalant.
Claim 4
Dependent Claim
29 words
A composition in accordance with claim 1, further including an anti-oxidant in an amount sufficient to substantially prevent oxidation of the unsaturations of said 8,11,14,17-eicosatetraenoic acid, salt or ester.
Claim 5
Dependent Claim
22 words
A composition in accordance with claim 3, wherein said anti-oxidant is selected such that it has both anti-oxidizing and lipoxygenase inhibiting activity.
Claim 6
Dependent Claim
18 words
A composition in accordance with claim 4, wherein said anti-oxidant is 1-phenyl-3-pyrazolidone, propyl gallate or a vitamin E.
Claim 7
Dependent Claim
18 words
A composition in accordance with claim 5, wherein said anti-oxidant is a combination of ascorbyl palmitate and γ-tocopherol.
Claim 8
Independent Claim
42 words
A method for the treatment of conditions caused by excessive release of SRS-A, comprising administering to a patient having such a condition an amount of 8,11,14,17-eicosa-tetraenoic acid or a pharmaceutically acceptable salt of ester thereof effective to inhibit the release of SRS-A.
Claim 9
Independent Claim
42 words
A method for the treatment of conditions caused by excessive release of SRS-A, comprising administering to a patient having such a condition an amount of 8,11,14,17-eicosa-tetraenoic acid or a pharmaceutically acceptable salt of ester thereof effective to inhibit the release of SRS-A.
Claim 10
Dependent Claim
18 words
A method in accordance with claim 7, wherein said administering step is accomplished by oral or nasal inhalation.
Claim 11
Dependent Claim
14 words
A method in accordance with claim 7, wherein said administering step is accomplished orally.
Claim 12
Dependent Claim
13 words
A method in accordance with claim 1, wherein said condition is bronchial asthma.
Claim 13
Dependent Claim
12 words
A method in accordance with claim 1, wherein condition is anaphylactic shock.
Claim 14
Dependent Claim
12 words
A method in accordance with claim 1, wherein condition is nasal congestion.
Claim 15
Dependent Claim
46 words
In a pressurized container for oral or nasal inhalation administration of unit dosages of a pharmaceutical composition contained therein, said container containing an active principle and a suitable propellant, the improvement wherein said active principle is 8,11,14,17-eicosatetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
Claim 16
Dependent Claim
46 words
In a pressurized container for oral or nasal inhalation administration of unit dosages of a pharmaceutical composition contained therein, said container containing an active principle and a suitable propellant, the improvement wherein said active principle is 8,11,14,17-eicosatetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
References Cited (Backward Citations)
US4377526A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-04-21 | 1989-10-21 | 1990-04-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-04-21 | 1993-10-21 | 1994-04-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-04-21 | 1997-10-21 | 1998-04-22 | $7700.00 | Window Closed / Lapsed |